ReviewColorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland2026
Rethinking lymphadenectomy in the immunotherapy era of colorectal cancer: A hypothesis-generating perspective.
Review in Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLymphadenectomy is traditionally central to curative colorectal cancer (CRC) surgery, with ≥ 12 retrieved lymph nodes being a well-recognised quality indicator influencing staging and local control. However, contemporary immunology reframes tumour-draining lymph nodes (TDLNs) as active co-ordinators of anti-tumour immunity.
aimThis article examines whether routine lymphadenectomy may theoretically impair systemic immune surveillance and immune checkpoint inhibitor (ICI) response, a concern most applicable to mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) disease. MATERIALS AND
methodsA review of surgical, oncological and immunological literature was performed, including comparison to breast cancer and melanoma, where sentinel lymph node biopsy (SLNB) and nodal preservation are standard.
resultsRetrospective CRC datasets demonstrate improved survival with increased nodal yield, though causality remains unproven and confounded by tumour biology, surgical quality and centre volume. Preclinical studies indicate TDLNs are essential for ongoing systemic immunity and optimal ICI effectiveness with early human data reporting improved outcomes with adjuvant immunotherapy. Evidence from breast cancer and melanoma provides indirect support for the concept of nodal preservation (SLNB ± observation) maintaining outcomes while reducing surgical morbidity, although lymphatic anatomy and systemic therapy differ from CRC. DISCUSSION: These concepts require further research to evaluate whether CRC surgical strategy in the immunotherapy era may need to balance oncological clearance against immune preservation. Selective nodal surgery guided by sentinel mapping or molecular tracers, integration with neoadjuvant and adjuvant immunotherapy trials, and molecular staging to reduce reliance on large nodal harvests represent key areas for investigation.
conclusionProspective, stratified trials, especially in dMMR/MSI-H vs. MSS cohorts, are needed to define when or if less may be more.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.